期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗心律失常药物应用和安全性评价进展 被引量：14

Advances in applications of anti-arrhythmia agents and safety evaluation
暂未订购
导出
摘要 抗心律失常药有治疗心律失常的作用,同时有致心律失常作用。临床上在应用各种抗心律失常药时,除了考虑充分利用其抗心律失常作用外,还应全面关注其安全性。本文通过对抗心律失常药物的作用机制以及对心律失常发生、维持机制的分析,对抗心律失常药物的应用和安全性评价进展作一综述。 Anti-arrhythmia agents have the therapeutic effect of anti-arrhythmia and could result in arrhythmia as well.When anti-arrhythmia drugs were applied clinically,considerations should not be given only to their anti-arrhythmia effect,but also to their overall safety.This paper is a comprehensive review directed at the applications of anti-arrhythmia drugs and safety evaluations,through analyses of the mechanism of anti-arrhythmia drugs,the occurrence and maintenance of arrhythmia involved.
作者 庄晓华 陈韬 徐涛 廖德宁
机构地区 上海市浦东医院心血管内科 解放军空军航空大学门诊部 第二军医大学长征医院心血管内科
出处 《药学服务与研究》 CAS CSCD 2012年第6期454-457,共4页 Pharmaceutical Care and Research
关键词 抗心律失常药 心律失常 药物副反应报告系统 综述 anti-arrhythmia agents arrhythmia adverse drug reactions reporting system review
分类号 R972.2 [医药卫生—药品] R541.7 [医药卫生—心血管疾病]
  • 相关文献

参考文献16

  • 1Haraguchi R, Ashihara T, Namba T, et al. Transmural dispersion of repolarization determines scroll wave behavior during ventricular tachyarrhythmias[J]. Circ J, 2011,75 ( 1 ) 80 88.
  • 2Viswanathan P C, Rudy Y. Cellular arrhythmogenic effects of congenital and acquired long QT syndrome in the heterogene ous myocardium[J]. Circulation,2000,101(10) :1192-1198.
  • 3Johnson D M,de Jong M M J ,Crijns H J G M,et at. Reduced ventricular proarrhythmic potential of the novel combined ion channel blocker AZD1305 z,ersus dofetilide in dogs with remodeled hearts[J]. Circ Arrhythm Electrophysiol,2012,5 (1):201-209.
  • 4王晓军,侯应龙.β受体阻滞剂在抗心律失常治疗中的应用[J].山东医药,2009,49(29):101-102. 被引量：4
  • 5Fauchier L, Pierre B, de Labriolle A, el al. Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta analysis of randomized controlled tr a s[J]. J Am Coll Cardiol. 2008, 51(8) :828-835.
  • 6张海澄.抗心律失常药物:从经验到循证再到分子机制治疗[J].中国心脏起搏与心电生理杂志,2010,24(5):379-381. 被引量：4
  • 7Vermes E, Tardif J C, Bourassa M G, et a l. Enalapril decrea- ses the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials [ J ]. Circulation, 2003,107(23) :2926-2931.
  • 8Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a histo- ry of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study[J]. J Am Coil Cardioh 2005,45(5):705-711.
  • 9Burashnikov A,Barajas Martinez H,Hu D,etal. Alrial selcc rive prolongation of refractory period with AVE0118 is dueprincipally to inhibition of sodium channel activity[J]. J Card iovasc Pharmacol, 2012. Epub ahead of print.
  • 10Scirica B M, Morrow D A, Hod H,et al. Effect of ranolazine, an amianginal agent with novel electrophysinlogical proper- ties, on the incidence of arrhythmias in patients with non ST segment elewltion acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 ( MERLIN TIMI 36) randomized controlled trial[J]. Circulation, 2007,116 (15) : 1647-1652.

二级参考文献20

  • 1Camm AJ, Kirchhof P, Lip GH, et al.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J].European Heart Journal,doi:10.1093/eurheartj/ehq278.
  • 2Eldstrom J, Wang Z, Xu H, et al.The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels[J].Mol Pharmacol,2007,72:1 522.
  • 3Dorian P, Pinter A, Mangat I, et al.The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans[J].Jcardiovasc Pharmacol,2007,50:35.
  • 4Dobrev D, Friedrich A, Voigt N, et al.The G protein-gated potassium current I(K,Ach) is constitutively active in patients with chronic atrial fibrillation[J]. Circulation,2005,112:3 697.
  • 5Burashnikov A, Di Diego JM, Zygmunt AC, et al.Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine[J].Circulation, 2007,116:1 449.
  • 6Schumacher SM, McEwen DP, Zhang L, et al.Antiarrhythmic drug-induced internalization of the atrial-specific K^+ channel Kv1.5[J].Circ Res,2009,104:1 390.
  • 7Watanabe H, Chopra N, Laver D, et al.Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans[J].Nat Med,2009,15:380.
  • 8Singh BN, Connolly SJ, Crijns HJ, et al.EURIDIS and ADONIS Investigators.Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J].N Engl J Med,2007,357:987.
  • 9Hohnloser SH, Crijns HJ, van Eickels M, et al.Effect of dronedarone on cardiovascular events in atrial fibrillation [J].N Engl J Med, 2009, 360 (7): 668.
  • 10Kober L, Torp-Pedersen C, McMurray JJ, et al.Increased mortality after dronedarone therapy for severe heart failure[J].N Engl J Med, 2008, 358 (25): 2 678.

共引文献5

同被引文献103

引证文献14

二级引证文献57

药学服务与研究
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部